Recognizing and treating urogenital atrophy in postmenopausal women

Journal of Women's Health

Volumn 19, Issue 3, 2010, Pages 425-432

  Goldstein, Irwin ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FEMRING; GESTAGEN; PLACEBO; POLYCARBOPHIL; PRASTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DYSPAREUNIA; ENDOMETRIAL DISEASE; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; HUMIDIFIER; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MASTALGIA; OSTEOPOROSIS; PATIENT EDUCATION; PATIENT MONITORING; PHYSICAL EXAMINATION; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; STROKE; URINARY TRACT INFECTION; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINA BLEEDING; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM;

ATROPHY; DEHYDRATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PHYSICAL EXAMINATION; POSTMENOPAUSE; VAGINA; VAGINAL DISEASES; VULVA;

EID: 77950289184     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1384     Document Type: Review

References (66)

1. American College of Obstetricians and Gynecologists Women's Healthcare Physicians. Genitourinary tract changes. Obstet Gynecol 2004;104:56S-61S.
2. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009. Epub ahead of print.
3. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005; 2(Suppl 3):154-165.
4. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric 2009;12:279-285.
5. Avis NE, Stellato R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning? Menopause 2000;7:297-309.
6. Graziottin A. Prevalence and evaluation of sexual health problems-HSDD in Europe. J Sex Med 2007;4(Suppl 3): 211-219.
7. Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 1982;248:445-448.
8. Schwenkhagen A. Hormonal changes in menopause and implications on sexual health. J Sex Med 2007;4(Suppl 3): 220-226.
9. Cohen BL, Barboglio P, Gousse A. The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med 2008;5:1418-1423.
10. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-666.
11. Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-yearold women. Maturitas 1996;24:31-36.
12. Utian WH, Schiff I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1:39-48.
13. Van Geelen JM, Van De Weijer PH, Arnolds HT. Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:9-14.
14. Clayton AH. Epidemiology and neurobiology of female sexual dysfunction. J Sex Med 2007;4(Suppl 4):260-268.
15. Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26:503-515.
16. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-774.
17. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292-303.
18. Molander U, Milsom I, Ekelund P, Mellstrom D. An epidemiological study of urinary incontinence and related urogenital symptoms in elderly women. Maturitas 1990; 12:51-60.
19. Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984; 63:257-260.
20. Pace G, Vicentini C. Female sexual function evaluation of the tension-free vaginal tape (TVT) and transobturator suburethral tape (TOT) incontinence surgery: Results of a prospective study. J Sex Med 2008;5:387-393.
21. Robinson D, Cardozo L. The pathophysiology and management of postmenopausal urogenital oestrogen deficiency. J Br Menopause Soc 2001;7:67-73.
22. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-369.
23. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228-231.
24. Freedman M. Sexuality in post-menopausal women. Menopausal Med 2000;8:1-5.
25. McCoy NL. Female sexuality during aging. In: Hof PR, Mobbs CV, eds. Functional neurobiology of aging. New York: Academic Press, 2001:769-779.
26. Cotreau MM, Chennathukuzhi VM, Harris HA, et al. A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas 2007;58:366-376.
27. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med 2000;9:S25-S32.
28. Bachmann GA, Ebert GA, Burd ID. Vulvovaginal complaints. In: Lobo RA, ed. Treatment of the postmenopausal woman: Basic and clinical aspects. Philadelphia, PA: Lippincott Williams & Wilkins, 1999:195-201.
29. Ballagh SA. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med 2005;23:126-140.
30. Wylie K, Daines B, Jannini EA, et al. Loss of sexual desire in the postmenopausal woman. J Sex Med 2007;4:395-405.
31. Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 2009; 12:106-113.
32. Nappi R, Salonia A, Traish AM, et al. Clinical biologic pathophysiologies of women's sexual dysfunction. J Sex Med 2005;2:4-25.
33. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(Suppl 1):S46-S52.
34. Baron JA, La VC, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990;162:502-514.
35. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: A literature review. Menopause 2004; 11:120-130.
36. Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med 2007;4(Suppl 3):235-253.
37. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2008;CD001321.
38. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-263.
39. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-180.
40. Bouchard C. Herbal alternatives as substitutes for hormone therapy in urogenital atrophy: Scientific evidence is needed. Menopause 2008;15:12-13.
41. Manonai J, Songchitsomboon S, Chanda K, Hong JH, Komindr S. The effect of a soy-rich diet on urogenital atrophy: A randomized, cross-over trial. Maturitas 2006;54:135-140.
42. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: Randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: The Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15:51-58.
43. Berman JR, Goldstein I. Female sexual dysfunction. Urol Clin North Am 2001;28:405-416.
44. Dennerstein L, Dudley EC, Hopper JL, Burger H. Sexuality, hormones and the menopausal transition. Maturitas 1997; 26:83-93.
45. Semmens JP, Tsai CC, Semmens EC, Loadholt CB. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol 1985;66:15-18.
46. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
47. Writing Group for the Women's Health Initiative Randomized Control Trial. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
48. Cicinelli E. Intravaginal oestrogen and progestin administration: Advantages and disadvantages. Best Pract Res Clin Obstet Gynaecol 2008;22:391-405.
49. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003;CD001500.
50. Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;22(Suppl):S43-S47.
51. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17b-Estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161.
52. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996; 103:351-358.
53. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: A comparative study. J Obstet Gynaecol Res 2001;27:255-260.
54. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: Preliminary results. Menopause 2002;9:179-187.
55. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustainedrelease vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107.
56. Crandall C. Vaginal estrogen preparations: A review of safety and efficacy for vaginal atrophy. J Womens Health 2002;11:857-877.
57. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999;10: 171-176.
58. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-93.
59. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiolreleasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145-154.
60. Mainini G, Scaffa C, Rotondi M, Messalli EM, Quirino L, Ragucci A. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17b-estradiol vaginal tablets. Clin Exp Obstet Gynecol 2005;32:111-113.
61. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Obstet Gynecol 2008;111:67-76.
62. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112: 1053-1060.
63. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-297.
64. Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health 2008;17:569-578.
65. Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008; 111:178-194.
66. Willhite LA, O'Connell MB. Urogenital atrophy: Prevention and treatment. Pharmacotherapy 2001;21:464-480.